ArticleCureus2025
Alpha-Gal on the Rise: The Alarming Growth of Alpha-Gal Syndrome in High-Risk Regions.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Evolution of alpha-Gal synthesis - a growing risk for alpha Gal syndrome.Annals of medicine · 2026Article
- Reversible Cationic Glycopolymer Hydrogels for RNA Delivery in Ticks.ACS polymers Au · 2026Article
- Perioperative Considerations for Alpha-Gal Syndrome: A Literature Review and Single-Center Experience in a Highly Endemic Area.Diseases (Basel, Switzerland) · 2026Review
- Alpha-Gal Syndrome in the Heartland: Dietary Restrictions, Public Awareness, and Systemic Barriers in Rural Kansas.Nutrients · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Mammalian meat allergy (MMA), increasingly linked to delayed hypersensitivity reactions such as alpha-gal syndrome, is a growing public health concern. This study evaluates the incidence, prevalence, and incidence rate of MMA in a large, diverse population of over 114 million individuals across two time periods (2015-2020 and 2021-2025), with stratification by age, sex, race, and ethnicity. Methods Using longitudinal electronic health record data, we calculated incidence proportion, prevalence, and incidence rate (cases per person-day) for MMA diagnoses. Analyses were stratified by demographic factors and compared across time windows. Predictive modeling was used to estimate future trends in high-risk populations. Results MMA increased dramatically across all demographics. Overall incidence proportion rose by over 5,500%, with the most substantial increases observed in individuals over 40 years old. Age-stratified analysis within racial groups revealed particularly sharp increases among Black (9,530%) and Hispanic (7,678%) adults over 40. Females experienced a steeper rise in incidence rate (11,169%) than males (7,426%). Predictive modeling projects continued growth through 2030, with incidence proportions in Black and Hispanic populations expected to increase by 57% and 72%, respectively. Conclusion MMA is emerging as a rapidly increasing diagnosis, particularly among middle-aged and older adults in racially diverse populations. These findings highlight the need for targeted public health efforts, including clinician education, adult-focused screening, and prevention strategies - especially in communities with rising allergy rates. Enhanced awareness and early identification are critical to mitigating the rising burden of this potentially life-threatening allergic condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.